Miller Fisher syndrome following Pfizer COVID-19 vaccine.
Neurol Sci
; 43(3): 1495-1497, 2022 Mar.
Article
in English
| MEDLINE | ID: covidwho-1530334
ABSTRACT
INTRODUCTION:
Miller Fisher syndrome (MFS) is a rare variant of Guillain-Barre syndrome characterized by ataxia, areflexia, and ophthalmoplegia. We present a case of MFS following Pfizer COVID-19 vaccine. CASE PRESENTATION A previously healthy 24-year-old female presented with binocular horizontal diplopia 18 days after receiving the first dose of Pfizer COVID-19 vaccine (Comirnaty®). Anti-ganglioside testing revealed positive anti-GQ1b antibodies. Intravenous immunoglobulins were administered, in a dose of 2 g per kg of body weight over 5 days. On a follow-up exam 3 weeks after the treatment, clinical improvement was noted with normal bulbomotor examination.CONCLUSION:
Patients with acute ophthalmoplegia occurring after COVID-19 vaccination should be screened for the presence of anti-GQ1b antibody. If the antibody is present, intravenous immunoglobulin should be administered as it may hasten clinical improvement.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Ophthalmoplegia
/
Miller Fisher Syndrome
/
COVID-19
Type of study:
Case report
/
Cohort study
/
Diagnostic study
/
Prognostic study
Topics:
Vaccines
/
Variants
Limits:
Adult
/
Female
/
Humans
/
Young adult
Language:
English
Journal:
Neurol Sci
Journal subject:
Neurology
Year:
2022
Document Type:
Article
Affiliation country:
S10072-021-05776-0
Similar
MEDLINE
...
LILACS
LIS